The integration of artificial intelligence (AI) into clinical management of
aortic stenosis (AS) has redefined our approach to the assessment and management
of this heterogenous valvular heart disease (VHD). While the large-scale early
detection of valvular conditions is limited by socioeconomic constraints, AI
offers a cost-effective alternative solution for screening by utilizing
conventional tools, including electrocardiograms and community-level
auscultations, thereby facilitating early detection, prevention, and treatment of
AS. Furthermore, AI sheds light on the varied nature of AS, once considered a
uniform condition, allowing for more nuanced, data-driven risk assessments and
treatment plans. This presents an opportunity to re-evaluate the complexity of AS
and to refine treatment using data-driven risk stratification beyond traditional
guidelines. AI can be used to support treatment decisions including device
selection, procedural techniques, and follow-up surveillance of transcatheter
aortic valve replacement (TAVR) in a reproducible manner. While recognizing
notable AI achievements, it is important to remember that AI applications in AS
still require collaboration with human expertise due to potential limitations
such as its susceptibility to bias, and the critical nature of healthcare. This
synergy underpins our optimistic view of AI’s promising role in the AS clinical
pathway.